Development and Optimization of a Sensitive Pseudovirus-based Assay for HIV-1 Neutralizing Antibodies Detection Using A3R5 Cells

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2017 Sep 22

PMID 28933644

Citations 16

Authors

Qingqing Chen

Jianhui Nie

Weijin Huang

Yanmei Jiao

Lan Li

Tong Zhang

Juan Zhao

Hao Wu

Youchun Wang

Affiliations

Soon will be listed here.

Abstract

Sensitive assays for HIV-1 neutralizing antibody detection are urgently needed for vaccine immunogen optimization and identification of protective immune response levels. In this study, we developed an easy-to-use HIV-1 pseudovirus neutralization assay based on a human CD4 lymphoblastoid cell line A3R5 by employing a high efficient pseudovirus production system. Optimal conditions for cell counts, infection time, virus dose and concentration of DEAE-dextran were tested and identified. For T-cell line-adapted tier 1 virus strains, significantly higher inhibitory efficiency was observed for both monoclonal neutralizing antibody (4 fold) and plasma (2 fold) samples in A3R5 than those in TZM-bl assay. For circulating tier 2 strains, the A3R5 pseudovirus assay showed even much higher sensitivity for both neutralizing antibody (10 fold) and plasma (9 fold) samples. When sequential neutralizing antibody seroconverting samples were tested in both A3R5 and TZM-bl assays, the seroconverting points could be detected earlier for tier 1 (15.7 weeks) and tier 2 (68.3 weeks) strains in A3R5 assay respectively. The high sensitive pseudovirus assay using more physiological target cells could serve as an alternative to the TZM-bl assay for evaluation of vaccine-induced neutralizing antibodies and identification of the correlates of protection.

Citing Articles

Applying Flow Virometry to Study the HIV Envelope Glycoprotein and Differences Across HIV Model Systems.

Burnie J, Fernandes C, Patel A, Persaud A, Chaphekar D, Wei D Viruses. 2024; 16(6).

PMID: 38932227 PMC: 11209363. DOI: 10.3390/v16060935.

Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.

Wu C, Raheem I, Nahas D, Citron M, Kim P, Montefiori D Proc Natl Acad Sci U S A. 2024; 121(22):e2317230121.

PMID: 38768344 PMC: 11145295. DOI: 10.1073/pnas.2317230121.

Assays Based on Pseudotyped Viruses.

Nie J, Wu X, Wang Y Adv Exp Med Biol. 2023; 1407:29-44.

PMID: 36920690 DOI: 10.1007/978-981-99-0113-5_2.

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.

Zhong J, Liu S, Cui T, Li J, Zhu F, Zhong N Emerg Microbes Infect. 2022; 11(1):2689-2697.

PMID: 36197655 PMC: 9639505. DOI: 10.1080/22221751.2022.2132881.

Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng.

Moon J, Jung Y, Moon S, Hwang J, Kim S, Kim M J Ginseng Res. 2022; 47(1):123-132.

PMID: 35855181 PMC: 9283196. DOI: 10.1016/j.jgr.2022.07.003.

References

Montefiori D, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza M . Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012; 206(3):431-41. PMC: 3392187. DOI: 10.1093/infdis/jis367. View

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F . Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194(12):1661-71. DOI: 10.1086/508748. View

Nie J, Wang W, Wen Z, Song A, Hong K, Lu S . Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China. J Virol Methods. 2012; 185(2):267-75. DOI: 10.1016/j.jviromet.2012.07.011. View

Mascola J, DSouza P, Gilbert P, Hahn B, Haigwood N, Morris L . Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005; 79(16):10103-7. PMC: 1182642. DOI: 10.1128/JVI.79.16.10103-10107.2005. View

Wei X, Decker J, Wang S, Hui H, Kappes J, Wu X . Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929):307-12. DOI: 10.1038/nature01470. View

Choudhry V, Zhang M, Harris I, Sidorov I, Vu B, Dimitrov A . Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun. 2006; 348(3):1107-15. PMC: 2268024. DOI: 10.1016/j.bbrc.2006.07.163. View

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C . Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. J Virol. 2016; 90(11):5231-5245. PMC: 4934761. DOI: 10.1128/JVI.00049-16. View

Hraber P, Seaman M, Bailer R, Mascola J, Montefiori D, Korber B . Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS. 2013; 28(2):163-9. PMC: 4042313. DOI: 10.1097/QAD.0000000000000106. View

Sarzotti-Kelsoe M, Bailer R, Turk E, Lin C, Bilska M, Greene K . Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2013; 409:131-46. PMC: 4040342. DOI: 10.1016/j.jim.2013.11.022. View

10.

Chong H, Hong K, Zhang C, Nie J, Song A, Kong W . Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr. 2008; 47(5):535-43. DOI: 10.1097/QAI.0b013e3181663967. View

11.

Euler Z, van den Kerkhof T, van Gils M, Burger J, Edo-Matas D, Phung P . Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol. 2011; 86(4):2045-55. PMC: 3302374. DOI: 10.1128/JVI.06091-11. View

12.

Plotkin S . Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401-9. DOI: 10.1086/589862. View

13.

Walker L, Huber M, Doores K, Falkowska E, Pejchal R, Julien J . Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011; 477(7365):466-70. PMC: 3393110. DOI: 10.1038/nature10373. View

14.

Binley J, Wrin T, Korber B, Zwick M, Wang M, Chappey C . Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23):13232-52. PMC: 524984. DOI: 10.1128/JVI.78.23.13232-13252.2004. View

15.

Mikell I, Sather D, Kalams S, Altfeld M, Alter G, Stamatatos L . Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011; 7(1):e1001251. PMC: 3020924. DOI: 10.1371/journal.ppat.1001251. View

16.

Sarzotti-Kelsoe M, Daniell X, Todd C, Bilska M, Martelli A, LaBranche C . Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods. 2014; 409:147-60. PMC: 4138262. DOI: 10.1016/j.jim.2014.02.013. View

17.

Nie J, Zhang C, Liu W, Wu X, Li F, Wang S . Genotypic and phenotypic characterization of HIV-1 CRF01_AE env molecular clones from infections in China. J Acquir Immune Defic Syndr. 2010; 53(4):440-50. DOI: 10.1097/QAI.0b013e3181cb8300. View

18.

Polonis V, Schuitemaker H, Bunnik E, Brown B, Scarlatti G . Impact of host cell variation on the neutralization of HIV-1 in vitro. Curr Opin HIV AIDS. 2010; 4(5):400-7. DOI: 10.1097/COH.0b013e32832edc50. View

19.

Ferrantelli F, Rasmussen R, Buckley K, Li P, Wang T, Montefiori D . Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis. 2004; 189(12):2167-73. DOI: 10.1086/420833. View

20.

McLinden R, LaBranche C, Chenine A, Polonis V, Eller M, Wieczorek L . Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One. 2013; 8(11):e77756. PMC: 3842913. DOI: 10.1371/journal.pone.0077756. View